Understanding the New EASL-EASD-EASO Guidelines on MASLD
New Clinical Practice Guidelines for MASLD, developed jointly by EASL, EASD, and EASO, update the 2016 guidelines to reflect recent advancements. They focus on early identification and intervention and the use of improved diagnostic tools and treatments to better manage MASLD and prevent clinical events. Created through a rigorous process of literature review, expert consensus, and stakeholder input, these guidelines provide a comprehensive framework for diagnosis, treatment, and follow-up, tailored to local resources and regulations. To learn more, review our summary or watch the most recent episode of GLI LIVE with Dr. Aleksander Krag, Secretary General of EASL.
GLI’s Liver Action Network Updates
Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment
The Fatty Liver Alliance is urging Canadians to support a petition for Madrigal Pharmaceuticals to apply for Health Canada approval of Rezdiffra, the first drug for treating MASH, a severe form of fatty liver disease. With 38% of Canadians potentially affected by MASLD and 20% of that group at risk of progressing to MASH, access to effective treatment is critical. Michael Betel, President and Founder of the Fatty Liver Alliance, emphasized, “Approval of Rezdiffra in Canada would be a monumental achievement, providing access to a proven treatment for those who need it most.” Sign the petition here.
Fatty Liver Risk Assessment Quiz Now Available on NASH kNOWledge Website
In preparation for their 6-year anniversary, NASH kNOWledge has unveiled a redesigned website, now at LiverAdvocates.org, featuring a new Fatty Liver Risk Assessment quiz to help users easily determine if they are at risk and should seek medical evaluation. Founder Tony Villiotti emphasizes, “This path really could have been avoided, and I believe I owe it to my donor and his family to help others. My life was saved for a reason.”
Emerging Insights
Highly Anticipated Clinical Trial Reveals a Surprising Foe of Fatty Liver Disease: An Odd-Chain Saturated Fat
A recent clinical trial suggests that a deficiency in C15:0, a nutrient found in dairy fat, may accelerate aging and contribute to conditions like fatty liver disease. The study found that C15:0 supplementation could improve liver function and overall metabolic health in affected individuals.
The Impact of Shift Work on NAFLD
A study found that shift work significantly increases the risk of developing NAFLD, particularly for young workers in their 20s. This risk is even higher in women and those with poor sleep quality, which underscores the need to address these factors in liver disease prevention.
⬇️ Provider Education Resources Available ⬇️
GLI continues to add to our continuing education programs. These CE programs offer healthcare providers valuable credits while enhancing their knowledge and skills in MASLD and MASH. Check out our newest programs below.
Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes
Through a partnership with the Global Learning Collaborative, GLI now offers this continuing education course on ReachMD. This series of bite-sized episodes will provide important information on MASLD and MASH in patients with type 2 diabetes. Drs. Naim Alkhouri and Robert Eckel and physician assistant Tessa Janovsky discuss best practices for screening, diagnosis, treatment, and management of MASH/MASLD.
Build Your Own Case Study | Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management
In collaboration with the Medical Learning Institute, GLI presents an interactive course to Build Your Own Case Study. Health Care Providers in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD and MASH and its associated risk factors, as well as feel confident about how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Upcoming GLI Events
- September 13-16, 2024: GLI’s Advanced Advocacy Academy (A3)
- September 12, 2024: Join us at our next Fatty Liver Disease Council – Policy Workgroup call. For more info email fattyliverdisease@globalliver.org.
We’re excited to announce that GLI will be participating in these upcoming conferences:
- September 5-6, 2024: Paris MASH Meeting
- September 24-26, 2024: 8th Annual MASH Drug Development Summit
- October 15-16, 2024: Reuters Pharma & Patient USA 2024
- October 24-25, 2024: MOSAIC – Global NASH/MASH Trialist Forum
- November 15-19, 2024: AASLD’s The Liver Meeting
Email us at info@globalliver.org to set up a meeting
